Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism-Reference-Cited by-同舟云学术

Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism

Published:2006-06-08 Issue:9 Volume:34 Page:1516-1522
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Gibbs John P.,Hyland Ruth,Youdim Kuresh

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference41 articles.

1. Allelic and functional variability of cytochrome P4502C9

2. THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

3. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

4. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine

5. Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Mechanism of Actions for Eugenol and Beta-Caryophyllene to Combat Colorectal Cancer Chemotherapy Using Network Pharmacology;Journal of Experimental Biology and Agricultural Sciences;2024-05-15

2. Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics;Clinical Drug Investigation;2024-04-10

3. Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes;Clinical Pharmacology & Therapeutics;2024-02-06

4. Phenotypic models of drug-drug-gene interactions mediated by cytochrome drug-metabolizing enzymes;2023-11-03

5. Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women?;Frontiers in Endocrinology;2021-10-08